TruthArchive.ai - Related Video Feed

Video Saved From X

reSee.it Video Transcript AI Summary

Over 100 members of Congress support a bill to fund Ozempic with Medicare at $1,500 a month, and most have taken money from Novo Nordisk, the drug's manufacturer. There is a push to recommend Ozempic for Americans as young as six for obesity, a condition claimed to be preventable. It is claimed that if 74% of Americans took Ozempic, the cost would be $3 trillion a year. Ozempic has made Novo Nordisk the biggest company in Europe, yet the Danish government recommends diet and exercise instead. It is claimed that for half the price of Ozempic, every American could receive regeneratively raised organic food and gym memberships. It is claimed that members of Congress are doing the bidding of Novo Nordisk instead of standing up for American farmers and children because Novo Nordisk is one of the largest funders of medical research.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker's administration will implement "most favored nations" drug pricing, ensuring Americans pay the lowest price for drugs compared to other developed countries. Some prescription drug prices will be reduced almost immediately by 50% to 90%. Big Pharma must voluntarily comply or the federal government will ensure equal pricing. To accelerate price reductions, the administration will cut out the middlemen to facilitate direct drug sales to American citizens at the most favored nation price. The speaker believes the middlemen are worse than drug companies because they don't make a product but make a fortune.

Video Saved From X

reSee.it Video Transcript AI Summary

One breast cancer drug costs over $16,000 per bottle in America. The same drug, from the same factory and company, costs one sixth the price in Australia. In Sweden, the identical product costs one tenth the American price.

Video Saved From X

reSee.it Video Transcript AI Summary

A businessman told the speaker that the same fat shot drug cost him $88 in London, but $1,300 in New York. He was stunned that the identical pill, made in the same plant by the same company, had such different prices. The speaker discussed this with drug company representatives. They argued for about half an hour, but ultimately the representative admitted there was no justification for the price difference.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

Video Saved From X

reSee.it Video Transcript AI Summary

Speaker contrasts health care in the US and Italy. They state that 'doctors in The US will prescribe antibiotics at any chance they can,' while noting that their boyfriend in Italy was sick and 'he went to his doctor, and his doctor told him to get rest and drink some milk before bed.' They ask, 'I'm sorry, but where is that information in The US?' and describe the difference as 'crazy to me the difference that we see between health care in America versus health care in Italy,' adding that this is 'one tiny example of how the system works in America versus Italy.' The remarks illustrate a perceived disparity in how health care systems operate across the two countries.

Video Saved From X

reSee.it Video Transcript AI Summary

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker states they capped prescription medication costs at $2,000 annually for seniors and insulin costs at $35 for seniors. They highlight that Black individuals are 60% more likely to be diagnosed with diabetes. The speaker claims that another plan would eliminate the insulin cost cap.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the current system was fair, even though the reasons why were not widely understood.

Video Saved From X

reSee.it Video Transcript AI Summary

The administration will secure "most favored nations" drug pricing, meaning Americans will pay the lowest price for drugs paid in other developed countries. Some prescription drug prices will be reduced almost immediately by 50 to 90%. Big Pharma will either abide by this principle voluntarily, or the federal government will ensure Americans pay the same price as other countries. To accelerate price reductions, the administration will cut out the middlemen and facilitate the direct sale of drugs at the most favored nation price directly to American citizens. The middlemen are considered worse than the drug companies because they don't make a product but make a fortune.

Video Saved From X

reSee.it Video Transcript AI Summary

The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the existing system was fair, even though the reasons why were not well understood. The speaker claims to have figured out the reasons behind this.

Video Saved From X

reSee.it Video Transcript AI Summary

A businessman told the speaker that the same fat shot drug cost him $88 in London but $1,300 in New York. The drugs were identical, made in the same plant by the same company. The speaker discussed this with a representative from the drug companies, who admitted there was no justification for the price difference.

Video Saved From X

reSee.it Video Transcript AI Summary

Politicians have long promised to eliminate the discrepancy between drug prices in the U.S. and Europe. This was a key issue for Bernie Sanders, but previous leaders haven't acted on it. Politicians make these promises knowing they likely won't have to fulfill them. The reason is that Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member.

Video Saved From X

reSee.it Video Transcript AI Summary

Over 100 members of Congress support a bill to fund Ozempic with Medicare at $1500 a month, and most have taken money from Novo Nordisk, the drug's manufacturer. Once approved for Medicare, it goes to Medicaid, and there's a push to recommend Ozempic for Americans as young as 6 for obesity, a condition claimed to be preventable and recently rare. With 74% of Americans obese, the cost of Ozempic prescriptions for all of them would be $3 trillion a year. Novo Nordisk's value is based on projected Ozempic sales to Americans, yet the Danish government recommends diet and exercise instead. For half the price of Ozempic, every American could receive regeneratively raised organic food and gym memberships. Congress is allegedly doing the bidding of Novo Nordisk instead of supporting American farmers and children because Novo Nordisk heavily funds medical research, the media, politicians, and medical schools.

Video Saved From X

reSee.it Video Transcript AI Summary

The U.S. has the most expensive healthcare system globally, spending significantly more per person than any other nation, yet achieving poorer outcomes. Life expectancy ranks 49th worldwide, and infant mortality is 54th. Additionally, a higher number of people live with multiple chronic conditions compared to other wealthy countries. This situation is alarming, yet many find healthcare unaffordable.

Video Saved From X

reSee.it Video Transcript AI Summary

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Video Saved From X

reSee.it Video Transcript AI Summary

Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary

One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

Video Saved From X

reSee.it Video Transcript AI Summary

Ozempic has rapidly become a cultural phenomenon, with one in eight US adults having tried GLP-1 drugs. The company producing Ozempic is now valued higher than Coca-Cola and McDonald's combined. Online discussions mention side effects like Ozempic face, hair loss, and severe stomach problems, alongside reports suggesting potential benefits for fertility, Alzheimer's, and even shopping addiction. The speaker questions the complete truth about GLP-1 drugs and weight loss, and has spent months researching and attempting to obtain GLP-1 medication.

Video Saved From X

reSee.it Video Transcript AI Summary

I've identified wasteful spending in Medicare, specifically with generic Cialis, or Tadalafil. In 2022, Medicare spent $237 million on this drug, averaging $481 per prescription across 492,000 prescriptions. However, at my pharmacy, the same prescription costs only $14 without insurance. That means it would only cost $7 million to cover the entire country at my pharmacy's pricing. The overcharge of $230 million for just this one drug is due to pharmacy benefits managers (PBMs). PBMs manage all pharmacy-related aspects for Medicare, deciding coverage, copays, government costs, and pharmacy payments. They've essentially decided on a 3000% markup. It's time to fire the PBMs and bring prices back to reality. To check the markups on your prescriptions, visit forestparkpharmacy.com and use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary

Politicians have long promised to address the discrepancy between drug prices in the U.S. and Europe. This issue was central to Bernie Sanders' presidential campaigns. However, these promises were never fulfilled because Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every member of Congress, the Senate, and the Supreme Court.

Video Saved From X

reSee.it Video Transcript AI Summary

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker stated that an individual in the UK paid a small amount for their shot, contrasting sharply with the $500 cost in the US. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world. The speaker questions the reason for this disparity.

Video Saved From X

reSee.it Video Transcript AI Summary

Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.

The Peter Attia Drive Podcast

327 - Choices, costs, and challenges in US healthcare: insurance, drug pricing, & potential reforms

Guests: Saum Sutaria

reSee.it Podcast Summary

The discussion centers on the complexities of the U.S. healthcare system, emphasizing the historical evolution of healthcare financing and the current challenges it faces. Saum Sutaria explains that insurance was originally designed for unpredictable, catastrophic events but has shifted to cover chronic illnesses, which now dominate healthcare expenditures. The U.S. spends nearly 20% of its GDP on healthcare, translating to about $4 trillion annually, with significant contributions from consumers, employers, and the government. Sutaria highlights that the employer-sponsored insurance model is unique to the U.S., where employers provide health insurance, often leading to a disconnect between consumers and actual healthcare costs. This model has resulted in a system where individuals are less sensitive to costs, contributing to rising expenditures. The conversation also touches on the administrative costs associated with healthcare, which are significantly higher in the U.S. than in other countries, partly due to the complexity of the system. The hosts discuss the historical context of healthcare reforms, including the Hill-Burton Act and the establishment of Medicare and Medicaid, which were responses to access issues post-World War II. They note that while these programs expanded coverage, they did not adequately address rising costs. The conversation shifts to the impact of chronic diseases, such as obesity and diabetes, on healthcare spending and outcomes, emphasizing that the U.S. has poorer life expectancy compared to other developed nations despite high spending. Sutaria explains that while the U.S. excels in treating chronic conditions once patients reach a certain age, it struggles with preventable issues in younger populations, such as maternal health and substance abuse. The discussion also covers the role of technology and innovation in healthcare, particularly the potential of AI to reduce administrative costs and improve patient care. The hosts express skepticism about the effectiveness of value-based care models and the challenges of implementing a universal healthcare system. They highlight the importance of addressing underlying health issues, such as nutrition and physical activity, to improve overall health outcomes. Sutaria concludes that while the healthcare system faces significant challenges, there is potential for improvement through policy changes and a focus on preventive care, which could help bend the cost curve towards GDP growth without drastic cuts.